|The WHO trial evaluated four potential medications for Covid-19, one of them is remdesivir.
It was among the first to treat coronavirus. The drug manufacturer Gilead rejected the findings of the trial. In a statement, reviewing the findings of the study is important.
WHO tested the effects of four potential treatments using the drug. The four drugs were tested with many patients. The results suggest that none of these treatments has an important effect on mortality or time spent in the hospital.
The emerging (WHO) data appears inconsistent, with more robust evidence from multiple randomized, controlled studies published in peer-reviewed journals validating the clinical benefit of this virus.
They are concerned the data from this open-label global trial has not undergone the rigorous review required to allow for constructive scientific discussion.
It could be a potential therapy since the beginning of the pandemic when it involved Donald Trump’s treatments.
There is a bit of uncertainty in the data, but the study says it “absolutely excludes” the idea can save a number of lives, and findings are the drug having no life-saving effect at all.
It is a similar message for preventing people from needing ventilation or speeding up people’s recovery.
So far, doctors have been raiding the cupboard for existing drugs that can fight coronavirus. The results have been disappointing with malaria drugs, HIV drugs, MS drugs, and now an Ebola drug.
Only an old steroid which is dexamethasone has proven life-saving. However, they are still waiting for the results, but new medicine will be expensive, and who gets to have them is a question.
What about other Covid treatments?
WHO was now looking at what’s next and looking at monoclonal antibodies and newer anti-viral drugs.
Meanwhile, the vaccine under development is safe and able to trigger immune responses. However, it was not sure whether the antibody vaccine-induced responses can protect from infection because the trial was not able to assess efficacy.
More Information About: